Long-term survival by surgery and adjuvant chemotherapy in a patient with perforated extranodal NK/T-cell lymphoma of the small intestine: a retrospective case study.
Adjuvant chemotherapy
Extranodal NK/T-cell lymphoma
Long-term survival
Nasal type
Perforation
Small intestine
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
12 Jun 2023
12 Jun 2023
Historique:
received:
26
02
2023
accepted:
06
06
2023
medline:
12
6
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
Extranodal natural killer/T-cell lymphoma, nasal type (ENKL) of the small intestine, is a disease with extremely poor prognosis. We describe treatment in a case which is novel in that it demonstrated long-term survival. A 68-year-old man was admitted to the emergency department of our hospital with the complaint of severe umbilical pain with tenderness and muscular defense. An abdominal computed tomography scan revealed a thick-wall mass on the small intestine and intra-abdominal free air. He was suspected of perforation of a small intestinal tumor and underwent emergency surgery. The surgery revealed a perforated tumor ulcer, and ENKL was diagnosed from the postoperative pathological findings. The patient's postoperative course was uneventful. He was further treated with adjuvant chemotherapy by hematologist comprising six courses of dexamethasone, etoposide, ifosfamide, and carboplatin. The patient demonstrated long-term survival and was in remission at the time of writing, four years and five months after surgery. We report a rare case of long-term survival of perforated ENKL of the small intestine achieved by surgery and adjuvant chemotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin. It is essential to consult with a hematologist to determine the most appropriate chemotherapy such as DeVIC if one encounters rare postoperative pathological findings of ENKL. To elucidate the pathophysiology of this disease and to prolong survival of affected patients, accumulation of cases of long-term survival and examination of associated characteristics is necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Extranodal natural killer/T-cell lymphoma, nasal type (ENKL) of the small intestine, is a disease with extremely poor prognosis. We describe treatment in a case which is novel in that it demonstrated long-term survival.
CASE PRESENTATION
METHODS
A 68-year-old man was admitted to the emergency department of our hospital with the complaint of severe umbilical pain with tenderness and muscular defense. An abdominal computed tomography scan revealed a thick-wall mass on the small intestine and intra-abdominal free air. He was suspected of perforation of a small intestinal tumor and underwent emergency surgery. The surgery revealed a perforated tumor ulcer, and ENKL was diagnosed from the postoperative pathological findings. The patient's postoperative course was uneventful. He was further treated with adjuvant chemotherapy by hematologist comprising six courses of dexamethasone, etoposide, ifosfamide, and carboplatin. The patient demonstrated long-term survival and was in remission at the time of writing, four years and five months after surgery.
CONCLUSIONS
CONCLUSIONS
We report a rare case of long-term survival of perforated ENKL of the small intestine achieved by surgery and adjuvant chemotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin. It is essential to consult with a hematologist to determine the most appropriate chemotherapy such as DeVIC if one encounters rare postoperative pathological findings of ENKL. To elucidate the pathophysiology of this disease and to prolong survival of affected patients, accumulation of cases of long-term survival and examination of associated characteristics is necessary.
Identifiants
pubmed: 37306807
doi: 10.1186/s40792-023-01688-7
pii: 10.1186/s40792-023-01688-7
pmc: PMC10260716
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103Informations de copyright
© 2023. The Author(s).
Références
Cancer Sci. 2005 Jun;96(6):349-52
pubmed: 15958057
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Gan To Kagaku Ryoho. 2021 Dec;48(13):1825-1827
pubmed: 35046343
J Clin Oncol. 2009 Nov 20;27(33):5594-600
pubmed: 19805668
J Clin Oncol. 2017 Jan;35(1):32-39
pubmed: 28034070
Zhonghua Xue Ye Xue Za Zhi. 2020 Oct 14;41(10):818-821
pubmed: 33190438
Oncotarget. 2016 Nov 1;7(44):72263-72275
pubmed: 27708217
J Clin Oncol. 2011 Nov 20;29(33):4410-6
pubmed: 21990393
Ann Oncol. 1994 May;5(5):397-400
pubmed: 8075046
J Clin Exp Hematop. 2017 Dec 27;57(3):98-108
pubmed: 28679966
Cancer. 1996 May 15;77(10):2137-49
pubmed: 8640683
J Hematol Oncol. 2013 Nov 16;6:86
pubmed: 24238138
Am J Surg Pathol. 1996 Jan;20(1):103-11
pubmed: 8540601
Front Pediatr. 2019 Apr 16;7:141
pubmed: 31041299
J Dermatol. 2005 Mar;32(3):204-9
pubmed: 15863868
Am J Surg Pathol. 2013 Jan;37(1):14-23
pubmed: 23232851
Crit Rev Oncol Hematol. 2007 Jul;63(1):65-71
pubmed: 17339119